29 results about "Poliomyelitis" patented technology

The invention relates to the field of medicines, and discloses application of doxazosin, thiobis (dichlorophenol) and diclophenol in preparation of medicines for preventing and / or treating enterovirus infection. The inventor finds that doxazosin mesylate, thiobichlorophenol and pharmaceutically acceptable salts or prodrugs thereof have a good inhibition effect on enteroviruses, especially poliovirus type 1, coxsackie virus group A type 9 and enterovirus type A71, and diclophenol has activity of resisting coxsackie virus. The method has an important clinical application value in treatment and prevention of related diseases caused by enterovirus infection.

Provided is a method of treating cancer in an individual by administering to the individual modified cells that express a chimeric antigen receptor (CAR) that contain a TIGIT extracellular domain that can bind to poliovirus receptor (PVR), a CD28 segment, and a CD3ζ segment. The modified cells may co-express and secrete a Bi-specific T cell engager (BiTE). The BiTE includes a segment that can specifically bind to human Folate Receptor alpha (FRα) and a segment that that can specifically bind to a human CD3□ segment. Modified cells that express the CAR, and may also express and secrete the BiTE, and polynucleotides encoding the CAR and the BiTE, are also provided.

The present application provides humanized antibodies and antigen binding fragments thereof that bind to human poliovirus (PVR). The antibodies are useful in the treatment of tumors or cancers. The present application also provides a method of treating a cancer in an individual afflicted with a cancer comprising administering to the individual a therapeutically effective amount of chimeric antigen receptor (CAR) NK or T cells.

This invention belongs to the field of biomedical technology, specifically disclosing a nanomicelle FluDox-MIC, its preparation method, and its uses. This nanomicelle is formed by the self-assembly of flumatinib and doxorubicin co-loaded in mPEG-DSPE, exhibiting pH-responsive release properties. Upon entering the tumor microenvironment, it releases the drug. The released flumatinib induces the degradation of the poliovirus receptor (PVR / CD155), relieving its inhibitory signal on NK cells and reactivating innate immune surveillance. Simultaneously, low-dose doxorubicin induces significant immunogenic cell death (ICD), initiating and amplifying tumor-specific T cell-mediated adaptive immunity. Through the synergistic activation of innate and adaptive immunity, the nanomicelle of this invention can effectively inhibit melanoma growth and overcome immunotherapy resistance, showing promising clinical application prospects.

The invention relates to the field of medicine, in particular to poliovirus type 2 virus-like particles and application thereof. The capsid protein of the virus-like particle comprises a capsid protein fragment VP2, a mutant capsid protein fragment sVP3 and a mutant capsid protein fragment sVP1 or a variant sVP1P29 thereof, and the capsid protein of the virus-like particle does not contain or contains a capsid protein fragment VP4; or the capsid protein of the virus-like particle comprises a mutant capsid protein fragment sVP3, a mutant capsid protein fragment sVP1 or a variant thereof, and a capsid protein fragment VP0 or a variant thereof. The heat stability and immunogenicity of the virus-like particle provided by the invention are superior to those of a wild type, so that the virus-like particle can be used as a candidate vaccine of PV2.

A production device, method and application of nano-sized zinc molybdate. The device includes a double-cone mixer; an elevator is obliquely provided at a bottom of a discharge port of the double-cone mixer; a rear end of the elevator is located above a feeder; the feeder is connected to one end of an electric heating converter, an other end of the electric heating converter is connected to a finished product bin; a top of the finished product bin is provided with an atomizing nozzle for adding nanomaterial dispersant; the atomizing nozzle is connected to a syringe pump by pipeline. High-purity nano-sized molybdenum trioxide and nano-sized zinc oxide are adopted to synthesize nano-sized zinc molybdate in an electric heating converter. The nano-sized zinc molybdate prepared by the device and method can be used for treatment of African swine fever virus, coronavirus, and AIDS phase I, Ebola, dengue fever, polio viruses.

The present disclosure describes, compositions and methods comprising a recombinant, chimeric poliovirus construct for the neuroinflammatory stimulation of microglia against neurodegenerative diseases. The compositions may include a chimeric poliovirus and a therapeutic agent capable of binding to protein aggregates associated with the neurodegenerative disease. Methods of treating neurodegenerative diseases and methods of activating microglia are also provided.

The present application relates to antibodies against poliovirus receptor (PVR) and uses thereof. The present invention provides humanized antibodies and antigen binding fragments thereof that bind to human poliovirus receptor (PVR). The antibodies can be used to treat tumors or cancers.

This application provides a poliovirus and method for treating human glioma, comprising a composition of oncolytic poliovirus and an Ommaya capsule, a delivery method, and uses.

Provided is a method of treating a tumor in an individual by neoadjuvant therapy, wherein the individual has not previously undergone treatment to effectively reduce tumor burden, the method comprising administering an oncolytic chimeric poliovirus construct, or an oncolytic chimeric poliovirus construct and an immune checkpoint inhibitor, followed by reduction of the tumor. The method may further comprise administration of immune checkpoint inhibitor or oncolytic chimeric poliovirus construct following reduction of tumor. Kits for performing the methods are also provided.

The present disclosure provides monoclonal antibodies that recognize human Nectin-2 (Nectin-2, Poliovirus Receptor-Related Protein-2, Poliovirus Receptor-Like 2, CDI12, or PRR-2, is a single pass transmembrane glycoprotein with two Ig-like C2-type domains and an Ig-like V-type domain) with high affinity and specificity and inhibit its binding to TIGIT and / or CD112R. The antibodies recognize the Nectin-2 protein (CD112), prevent its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT) and CD112R (PVRIG) and inhibit suppressive activity on lymphocytes such as natural killer (NK) cells and T-cells. The disclosure further provides pharmaceutical and methods for use in cancer immunotherapy and in diagnosis. The disclosure finally further provides chimeric antigen receptor (CAR) comprising scFv antibody binding to Nectin-2.

We provide antibody-based therapeutics against CD155 that can treat CNS cancers and systemic cancers. [Solution] Humanized antibodies or antigen-binding fragments specific to the poliovirus receptor (PVR) are used to prepare antibody-drug conjugates (ADCs) that target nucleic acids, peptides, proteins, drugs, and radiopharmaceuticals to cancer cells. These antibodies can be used for checkpoint blockade, blocking PVR (CD155) from binding to TIGIT. Humanized antibodies are used either alone or in combination with other checkpoint inhibitors known in the art. Humanized antibodies modulate the PVR-DNAM-1 axis to upregulate DNAM1 (CD226) expression on T cells or NK cells, thereby restoring the immune surveillance mechanism. The antibodies are incorporated into CAR-T cells or CAR NK cells.

To provide a compound of formula (I) as described herein, pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods for using these compounds, salts, and compositions to treat viral infections. [Solution] The present invention relates to a novel 1,3-dioxoindene compound that is an inhibitor of picornaviruses, including coxsackievirus, enterovirus, echovirus, poliovirus, and rhinovirus, and is therefore useful for treating viral infections, including polio, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular diseases, hepatitis A, myositis, myocarditis, pancreatitis, diabetes mellitus, epidemic myalgia, encephalitis, common cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis, or otitis media.

The present invention provides humanized antibodies and antigen binding fragments thereof that bind to human poliovirus (PVR). The antibodies are useful in the treatment of tumors or cancers.

The invention discloses a method for printing a human exoskeleton based on 3D. The method comprises the following steps: S1, performing three-dimensional scanning on the appearance shape of a human body; s2, performing transmission and three-dimensional construction on the scanned human body information; s3, three-dimensional design of the human exoskeleton; s4, human body exoskeleton printing is conducted through a 3D printer; s5, the entity obtained through 3D printing is polished; through three-dimensional scanning of the human body appearance shape, three-dimensional model construction of the human body exoskeleton and selection and use of the joint connection structures through the joint model library, the robot better fits the human body joint curvature, and through design of connection end points through the squatting and rising assisting module, installation and connection of a spring or a hydraulic mechanism are facilitated; and after the human exoskeleton is subjected to three-dimensional model scanning processing, the 3D printer is controlled to operate according to a three-dimensional model scanning result, so that the 3D printer can print the exoskeleton.

The present invention provides a reagent for detecting a protein for use in preparing a product for diagnosing aggressive behavior in schizophrenia. The protein is serum polio receptor protein, whose amino acid sequence is shown in SEQ NO. 1. The present invention utilizes high-throughput combined analysis of transcriptomics, proteomics, and metabolomics to screen for differentially expressed molecules between aggressive and non-aggressive schizophrenia groups. Combined with bioinformatics analysis of the interactions among the three, the present invention screens for differentially expressed proteins between the aggressive and non-aggressive schizophrenia groups. Further validation with expanded sample sizes reveals that the differentially expressed protein, serum polio receptor protein, exhibits a difference between the two groups (P < 0.05), and can serve as a potential biomarker for determining aggressive behavior in schizophrenia.

The invention relates to fast-acting viricidal compositions and methods of using the same, wherein the compositions are capable of removing soil and effectively inactivating a wide variety of viral pathogens, particularly small, non-enveloped viruses such as poliovirus and norovirus. The compositions are especially useful on hard surfaces, and can easily be applied to a service to provide rapid viricidal efficacy.

The invention provides a method for detecting residual blood through object surface disinfection wet tissue, and relates to the technical field of medical environment, medical equipment and equipment surface cleaning detection. After the object surface disinfection wet tissue with the residual blood detection function is used for collecting surface samples of a medical environment, a medical instrument and equipment, the residual blood pollution degree of the surfaces of the medical environment, the medical instrument and the equipment is qualitatively, semi-quantitatively and quantitatively judged according to the color change of the object surface disinfection wet tissue with the residual blood detection function. The semi-quantitative detection calibrator comprises multiple stages of color blocks and subdivision grids, and the residual blood volume is calculated by counting the area proportion of different color blocks through visual inspection; according to the quantitative detection AI rule, wet tissue images are scanned through photography and analysis equipment, software analyzes the mapping relation between pixel RGB values and standard concentration, the method is easy and convenient to operate, large-batch data can be rapidly processed, the cost is remarkably reduced, and the method is particularly suitable for rapid pollution evaluation of medical environments, medical instruments and equipment surfaces. Meanwhile, the pirameton can generate a composite reaction with other components in the object surface disinfection wet tissue with the residual blood detection function, so that the sterilization and disinfection capability of the product is improved; through detection, the killing rate of the object surface disinfection wet tissue with the residual blood detection function on microorganisms such as staphylococcus aureus, escherichia coli and pseudomonas aeruginosa within one minute is as high as 99.999%, and the killing rate of the object surface disinfection wet tissue on poliovirus is as high as 99.99%.

Arrays comprising probes from at least two polioviruses selected from poliovirus type 1, poliovirus type 2 and poliovirus type 3 are provided. Arrays comprising a plurality of probes comprising short peptide probes from at least one poliovirus are also provided. Methods of using the arrays, as well as kits and systems comprising the arrays are also provided.

The invention relates to a preparation method of a poliovirus solution, which comprises the following steps in sequence: a) providing cells which exist in a culture medium; b) regulating the cells to a proper cell density, and then contacting the poliovirus with the cells to obtain a mixed solution of the poliovirus and the cells; c) centrifuging the mixed solution, and collecting supernate; and d) purifying the supernate through a chromatographic step to obtain the poliovirus solution.

A modified polio virus receptor (PVR / CD155) gene including one or more mutations in exons selected from exons 2, 3 and 4 of poliovirus receptor (PVR / CD155) gene having SEQ ID No.1. More specifically, cell lines including the modified gene and method of producing the same using clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (CRISPR-Cas9) system. The cell line is refractory (non-permissive) to poliovirus and susceptible to most Enteroviruses and many other human viruses. Further, the cell line can be applied in the fields of research, diagnostic and therapy.

The present disclosure provides monoclonal antibodies that recognize human Nectin-2 (Nectin-2, Poliovirus Receptor-Related Protein-2, Poliovirus Receptor-Like 2, CD112, or PRR-2, is a single pass transmembrane glycoprotein with two Ig-like C2-type domains and an Ig-like V-type domain) with high affinity and specificity and inhibit its binding to TIGIT and / or CD112R. The antibodies recognize the Nectin-2 protein (CD112), prevent its binding to T cell immunoreceptor with Ig and ITIM domains (TIGIT) and CD112R (PVRIG) and inhibit suppressive activity on lymphocytes such as natural killer (NK) cells and T-cells. The disclosure further provides pharmaceutical and methods for use in cancer immunotherapy and in diagnosis. The disclosure finally further provides chimeric antigen receptor (CAR) comprising scFv antibody binding to Nectin-2.

The invention relates to the field of medicine, in particular to preparation of poliovirus type 1 thermostable virus-like particles and immunogenicity research of the poliovirus type 1 thermostable virus-like particles. The invention provides a poliovirus type 1 virus-like particle, which is selected from any one of the following: a, a capsid protein of the virus-like particle comprises a mutant capsid protein fragment sVP2, a mutant capsid protein fragment sVP3 and a mutant capsid protein fragment sVP1; the capsid protein of the virus-like particle does not contain or contains a mutant capsid protein fragment sVP4; and b, the capsid protein of the virus-like particle comprises a mutant capsid protein fragment sVP0 or a variant thereof, a mutant capsid protein fragment sVP3 and a mutant capsid protein fragment sVP1 or a variant thereof. According to the application, capsid proteins are connected in series at intervals through an operable element, the VLP is successfully prepared in pichia pastoris through sequence optimization, and the purified VLP is named as an sVLP series. The thermal stability result shows that the thermal stability of the sVLP series is far better than that of the wild type VLP (wtVLP), and the sVLP series can tolerate higher temperature; in addition, animal immune tests show that the immunogenicity of the sVLP series is better, and the neutralizing titer of immune serum of the sVLP series is far higher than that of wtVLP immune serum. In conclusion, the sVLP series is a good candidate strategy for PV1 vaccines.

Provided is a method of treating cancer in an individual by administering to the individual modified cells that express a chimeric antigen receptor (CAR) that contain a TIGIT extracellular domain that can bind to poliovirus receptor (PVR), a CD28 segment, and a CD3ζ segment. The modified cells may co-express and secrete a Bi-specific T cell engager (BiTE). The BiTE includes a segment that can specifically bind to human Folate Receptor alpha (FRα) and a segment that that can specifically bind to a human CD3ε segment. Modified cells that express the CAR, and may also express and secrete the BiTE, and polynucleotides encoding the CAR and the BiTE, are also provided.

The invention discloses a special-effect traditional Chinese medicine formula for rheumatic diseases, and relates to the technical field of rheumatic traditional Chinese medicines. The invention relates to a traditional Chinese medicine composition for treating rheumatic diseases, which is prepared by grinding raw medicinal materials into fine powder, filling into a gauze bag and soaking in pure grain brewed wine, the mass ratio of the medicinal materials to the wine is (1: 5)-(1: 10), the medicinal wine is orally taken or externally applied, the medicinal wine is orally taken twice a day, 30-50ml of medicinal wine is taken each time, and the medicinal wine is externally applied to an affected part 3-5 times a day. Clinical observation shows that the arthralgia VAS score of 93% of patients within 7 days is reduced by more than or equal to 50%; the dual administration has the advantages that immunity is regulated by oral administration, and affected parts are directly penetrated by external application; safety is improved, and the liver and kidney toxicity incidence rate is smaller than 1% through the processing technology and dosage control; multiple diseases are covered, and the traditional Chinese medicine composition has an obvious effect on sequelae of rheumatic arthritis, rheumatoid and poliomyelitis.

This invention discloses the novel Formula (I) [4,4'-disulfanediylbis(N-(4-morpholinobenzylidene)aniline)] compound for use in the treatment of diseases caused by viruses, particularly Herpes simplex virus-1, human Poliovirus, Adenovirus and Bovine coronavirus, the form of this compound in a structure conjugated with G- GQDs (glutathione-functionalised graphene quantum dots) and the synthesis method thereof.

The invention relates to the field of medicine, in particular to preparation of poliovirus type 3 thermostable virus-like particles and immunogenicity research of the poliovirus type 3 thermostable virus-like particles. The invention provides a poliovirus type 3 virus-like particle. The poliovirus type 3 virus-like particle is selected from any one of the following: a, a capsid protein of the virus-like particle comprises a mutant capsid protein fragment sVP2, a mutant capsid protein fragment sVP3 and a mutant capsid protein fragment sVP1; and b, the capsid protein of the virus-like particle comprises a mutant capsid protein fragment sVP0 or a variant thereof, a mutant capsid protein fragment sVP3 and a mutant capsid protein fragment sVP1 or a variant thereof. According to the application, capsid proteins are connected in series at intervals through an operable element, the VLP is successfully prepared in pichia pastoris through sequence optimization, and the purified VLP is named as an sVLP series. The thermal stability result shows that the thermal stability of the sVLP series is far better than that of the wild type VLP (wtVLP), and the sVLP series can tolerate higher temperature; in addition, animal immune tests show that the immunogenicity of the sVLP series is better, and the neutralizing titer of immune serum of the sVLP series is far higher than that of wtVLP immune serum. In conclusion, the sVLP series is a good candidate strategy for PV3 vaccines.

Emulsion-based and micromolded (“MM”) or three dimensional printed (“3DP”) polymeric formulations for single injection of antigen, preferably releasing at two or more time periods, have been developed. Formulations are preferably formed of biocompatible, biodegradable polymers. Discrete regions encapsulating antigen, alone or in combination with other antigens, adjuvants, stabilizers, and release modifiers, are present in the formulations. Antigen is preferably present in excipient at the time of administration, or on the surface of the formulation, for immediate release, and incorporated within the formulation for release at ten to 45 days after initial release of antigen, optionally at ten to 90 day intervals for release of antigen in one or more additional time periods. Antigen may be stabilized through the use of stabilizing agents such as trehalose glass. In a preferred embodiment for immunization against polio, antigen is released at the time of administration, and two, four and six months thereafter.